Patents Assigned to Texas Biomedical Research Institute
-
Publication number: 20220409602Abstract: Provided here are arylpiperazine pharmacophore compositions that mitigate levodopa-induced dyskinesia and significantly improve Parkinson's disease-like symptoms. These dopamine D3 receptor ligands have high affinity and selectivity, are orally active, and have desirable drug-like properties.Type: ApplicationFiled: June 14, 2022Publication date: December 29, 2022Applicant: TEXAS BIOMEDICAL RESEARCH INSTITUTEInventor: Marcel M. Daadi
-
Patent number: 10751406Abstract: The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.Type: GrantFiled: August 8, 2017Date of Patent: August 25, 2020Assignee: TEXAS BIOMEDICAL RESEARCH INSTITUTEInventors: Marie-Claire Gauduin, Philippe Blancou
-
Patent number: 10125173Abstract: The invention provides methods, compositions and kits for treating and or preventing an HIV infection. For example, HIV envelope-like polypeptides (wild-type HIV polypeptides and mimotopes) may be administered to an individual so as to induce a protective immune response to HIV. Alternatively, antibodies directed to the HIV envelope-like polypeptides may be administered to an individual to treat or prevent an HIV infection and/or one or more symptoms associated with the infection (e.g., AIDS).Type: GrantFiled: April 8, 2016Date of Patent: November 13, 2018Assignee: Texas Biomedical Research InstituteInventors: Ruth M. Ruprecht, Michael Humbert
-
Patent number: 10111881Abstract: Described herein are pharmaceutical compositions capable of inhibiting vesicle formation and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat pathogenic infections.Type: GrantFiled: April 4, 2017Date of Patent: October 30, 2018Assignee: Texas Biomedical Research InstituteInventors: Robert Andrew Davey, Manu Anantpadma
-
Patent number: 9730996Abstract: The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.Type: GrantFiled: October 24, 2013Date of Patent: August 15, 2017Assignee: Texas Biomedical Research InstituteInventors: Marie-Claire Gauduin, Philippe Blancou
-
Publication number: 20160068917Abstract: Baboon Adenovirus (BaAdV)-2/4 and BaAdV-3 are disclosed herein. BaAdV-2/4 and BaAdV-3 polynucleotide, polypeptides and antibodies that specifically bind BaAdV-2/4 and/or BaAdV-3 are disclosed. Methods are disclosed for detecting BaAdV-2/4 and BaAdV-3. Methods are also disclosed for treating, preventing, and inducing an immune response to BaAdV-2/4 and/or BaAdV-3. Kits are also provided.Type: ApplicationFiled: November 17, 2015Publication date: March 10, 2016Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, TEXAS BIOMEDICAL RESEARCH INSTITUTE, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARInventors: Charles Chiu, Jean Patterson, Mary Michelle Leland, Kenneth Dee Carey, Dean Ehrdman
-
Patent number: 9222142Abstract: Baboon Adenovirus (BaAdV)-2/4 and BaAdV-3 are described herein. BaAdV-2/4 and BaAdV-3 polynucleotide, polypeptides and antibodies that specifically bind BaAdV-2/4 and/or BaAdV-3 are described. Methods are described for detecting BaAdV-2/4 and BaAdV-3. Methods are also described for treating, preventing, and inducing an immune response to BaAdV-2/4 and/or BaAdV-3. Kits are also provided.Type: GrantFiled: January 15, 2014Date of Patent: December 29, 2015Assignees: The Regents of the University of California, The United States of America as represented by the Secretary of the Department of Health and Human Services, Texas Biomedical Research InstituteInventors: Charles Chiu, Jean Patterson, Mary Michelle Leland, Kenneth Dee Carey, Dean Ehrdman
-
Publication number: 20140243234Abstract: The present inventions relate to the selection and production of specific proteins or peptides with desired properties. The inventions relate to the agents and methods of identifying select peptides or proteins with specific binding properties or greater enzymatic performance from vast numbers of variants.Type: ApplicationFiled: August 3, 2012Publication date: August 28, 2014Applicant: TEXAS BIOMEDICAL RESEARCH INSTITUTEInventor: Andrew Hayhurst
-
Publication number: 20140178426Abstract: The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.Type: ApplicationFiled: October 24, 2013Publication date: June 26, 2014Applicant: Texas Biomedical Research InstituteInventors: Marie-Claire Gauduin, Philippe Blancou